Albuterol and Ipratropium Oral Inhalation: MedlinePlus Drug Information

The combination of albuterol and ipratropium comes as a solution (liquid) to inhale by mouth using a nebulizer (machine that turns medication into a mist that can be inhaled) and as a spray to inhale by mouth using an inhaler. It is usually inhaled four times a day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use albuterol and ipratropium exactly as directed. Do not use more or less of it or use it more often than prescribed by your doctor.

Your doctor may tell you to use additional doses of albuterol and ipratropium inhalation if you experience symptoms such as wheezing, difficulty breathing, or chest tightness. Follow these directions carefully, and do not use extra doses of medication unless your doctor tells you that you should. Do not use more than 2 extra doses of the nebulizer solution per day. Do not use the inhalation spray more than six times in 24 hours.

Call your doctor if your symptoms worsen, if you feel that albuterol and ipratropium inhalation no longer controls your symptoms, or if you find that you need to use extra doses of the medication more often.

If you are using the inhaler, your medication will come in cartridges. Each cartridge of albuterol and ipratropium inhalation spray is designed to provide 120 inhalations. This is enough medication to last one month if you use one inhalation four times a day. After you use all 120 doses, the inhaler will lock and will not release any more medication, There is a dose indicator on the side of the inhaler that keeps track of how much medication is left in the cartridge. Check the dose indicator from time to time to see how much medication is left. When the pointer on the dose indicator enters the red area, the cartridge contains enough medication for 7 days and it is time to refill your prescription so that you will not run out of medication.

Be careful not to get albuterol and ipratropium inhalation into your eyes. If you get albuterol and ipratropium in your eyes, you may develop narrow angle glaucoma (a serious eye condition that may cause loss of vision). If you already have narrow angle glaucoma, your condition may worsen. You may experience widened pupils (black circles in the center of the eyes), eye pain or redness, blurred vision, and vision changes such as seeing halos around lights, or seeing unusual colors Call your doctor if you get albuterol and ipratropium into your eyes or if you develop these symptoms.

The inhaler that comes with albuterol and ipratropium spray is designed for use only with a cartridge of albuterol and ipratropium. Never use it to inhale any other medication, and do not use any other inhaler to inhale the medication in a cartridge of albuterol and ipratropium.

Before you use albuterol and ipratropium inhalation for the first time, read the written instructions that come with the inhaler or nebulizer. Ask your doctor, pharmacist, or respiratory therapist to show you how to use it. Practice using the inhaler or nebulizer while he or she watches.

To prepare the inhaler for use, follow these steps:

1. Put the inhaler together before you use it for the first time. To start, take the inhaler out of the box, and keep the orange cap closed. Press the safety catch and pull off the clear base of the inhaler. Be careful not to touch the piercing element inside of the base
2. The inhaler must be discarded three months after you put it together. Write this date on the label of the inhaler so you will not forget when you need to discard your inhaler.
3. Take the cartridge out of the box and insert the narrow end into the inhaler. You can press the inhaler against a hard surface to be sure it is inserted correctly. Replace the clear plastic base on the inhaler.
4. Hold the inhaler upright with the orange cap closed. Turn the clear base in the direction of the white arrows until it clicks.
5. Flip the orange cap so that it is fully open. Point the inhaler toward the ground.
6. Press the dose release button. Close the orange cap.
7. Repeat steps 4-6 until you see a spray coming out of the inhaler. Then repeat these steps three more times.
8. The inhaler is now primed and ready for use. You will not need to prime your inhaler again unless you do not use it for longer than 3 days. If you do not use your inhaler for more than 3 days, you will need to release one spray toward the ground before you start to use it again. If you do not use your inhaler for more than 21 days, you will need to follow steps 4-7 to prime the inhaler again.

To inhale the spray using the inhaler, follow these steps:

1. Hold the inhaler upright with the orange cap closed. Turn the clear base in the direction of the white arrows until it clicks.
2. Open the orange cap.
3. Breathe out slowly and completely.
4. Place the mouthpiece in your mouth and close your lips around it. Be careful not to cover the air vents with your lips.
5. Point the inhaler toward the back of your throat and breathe in slowly and deeply.
6. While you are breathing in, press the dose release button. Continue to breathe in as the spray is released into your mouth.
7. Hold your breath for 10 seconds or as long as you comfortably can.
8. Take the inhaler out of your mouth and close the orange cap. Keep the cap closed until you are ready to use the inhaler again.

To inhale the solution using a nebulizer, follow these steps:

1. Remove one vial of medication from the foil pouch. Put the rest of the vials back into the pouch until you are ready to use them.
2. Twist off the top of the vial and squeeze all of the liquid into the reservoir of the nebulizer.
3. Connect the nebulizer reservoir to the mouthpiece or face mask.
4. Connect the nebulizer reservoir to the compressor.
5. Put the mouthpiece in your mouth or put on the face mask. Sit in a comfortable, upright position and turn on the compressor.
6. Breathe in calmly, deeply, and evenly through your mouth for about 5 to 15 minutes until mist stops forming in the nebulizer chamber.

Clean your inhaler or nebulizer regularly. Follow the manufacturer’s directions carefully and ask your doctor or pharmacist if you have any questions about cleaning your inhaler or nebulizer.

Albuterol Sulfate Inhalation: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

Read the Patient Information Leaflet provided by your pharmacist before you start using this medication and each time you get a refill. This medication is used with a special machine called a nebulizer that changes the solution to a fine mist that you inhale. Learn all instructions for the use of this medication and the nebulizer. If a child is using this medication, a parent or other responsible adult should supervise the child. If you have any questions, consult your doctor, pharmacist, or respiratory therapist.

This product should be clear and colorless to light yellow. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Use the dropper supplied by the manufacturer to carefully measure the prescribed amount of medication and place in the nebulizer with sterile saline as directed. If you are using the single dose package, empty the contents of the package in the nebulizer and add sterile saline as directed. Gently swirl the nebulizer to mix the solution.

Do not rinse the dropper. Replace the dropper and tightly close the bottle after each use. To avoid contamination, do not touch the dropper tip or let it touch any other surface. Discard any unused mixed solution. Do not save for future use.

Using a mouthpiece or face mask with the nebulizer, inhale the prescribed dose of medication into your lungs as directed by your doctor, usually 3 or 4 times daily as needed. Each treatment usually takes about 5 to 15 minutes. Use this medication only through a nebulizer. Do not swallow or inject the solution. Do not mix with other medicines in your nebulizer. To prevent infections, clean the nebulizer and mouthpiece/face mask according to the manufacturer’s directions.

Dosage is based on your medical condition, age, weight, and response to treatment. Do not increase your dose or use this drug more often than prescribed without your doctor’s approval. Using too much of this medication will increase your risk of serious (possibly fatal) side effects.

Learn which of your inhalers/medications you should use every day (controller drugs) and which you should use if your breathing suddenly worsens (quick-relief drugs). Ask your doctor ahead of time what you should do if you have new or worsening cough or shortness of breath, wheezing, increased sputum, worsening peak flow meter readings, waking up at night with trouble breathing, if you use your quick-relief inhaler/medication more often (more than 2 days a week), or if your quick-relief inhaler/medication does not seem to be working well. Learn when you can treat sudden breathing problems by yourself and when you must get medical help right away.

Tell your doctor if your symptoms do not improve or if they worsen.

The Diagnosis and Treatment of Wheezing

How Do I Find Out the Cause of My Wheezing?

To determine the cause of your wheezing, your doctor will ask questions about your symptoms and what triggers them. For example, if you have no history of lung disease and you always wheeze after eating a certain food or at a certain time of year, the doctor may suspect that you have a food or respiratory allergy.

The doctor will listen to your lungs with a stethoscope to hear where the wheezing is and how much wheezing you have.

If this is the first time you’ve been evaluated, your doctor will probably ask you to perform a breathing test (spirometry) and may also order a chest X-ray.

Other blood tests and procedures may be necessary, depending on what the doctor learns from interviewing and examining you.

If it seems like allergies may be related to your wheezing, there are a variety of other tests your doctor may use to verify allergies, including skin testing or blood tests.

What Are the Treatments for Wheezing?

First off, see a doctor to determine the cause of your wheezing and then receive treatment for the specific cause.

If wheezing is caused by asthma, your doctor may recommend some or all of the following to reduce inflammation and open the airways:

• A fast-acting bronchodilator inhaler — albuterol (Proventil HFA, Ventolin HFA), levalbuterol (Xopenex) — to dilate constricted airways when you have respiratory symptoms
• An inhaled corticosteroid — beclomethasone (Qvar), budesonide (Pulmicort), ciclesonide (Alvesco), flunisolide (Aerospan), fluticasone (Flovent), mometasone (Asmanex)
• A long-acting bronchodilator/corticosteroid combination — budesonide/formoterol (Symbicort), fluticasone/salmeterol (Advair)
• A long-acting anticholinergic — tiotropium bromide (Spiriva Respimat). This drug is used in addition to a regular maintenance medication for better symptom control, and is available for use by anyone age 6 years and older.
• An asthma controller pill to reduce airway inflammation — montelukast (Singulair), zafirlukast (Accolate)
• A non-sedating antihistamine pill — cetirizine (Zyrtec), fexofenadine (Allegra), loratadine (Claritin, Alavert) — or a prescription nasal spray — budesonide (Rhinocort), fluticasone propionate (Flonase), mometasone furoate (Nasonex), triamcinolone acetonide (Nasacort AQ) — if you have nasal allergies. Flonase, Nasacort Allergy 24HR and Rhinocort Allergy are also available over the counter.

If you have acute bronchitis, your doctor may recommend some or all of the following:

Generally, any mild wheezing that accompanies acute bronchitis disappears when the infection does.

Call 911 if you have any difficulty breathing. In emergencies, a medical team may administer any of the following:

What Do I Need to Know?

Choose an AuthorAaron Barber, AT, ATC, PESAbbie Roth, MWCAdam Ostendorf, MDAdriane Baylis, PhD, CCC-SLPAdrienne M. Flood, CPNP-ACAdvanced Healthcare Provider CouncilAila Co, MDAlaina White, AT, ATCAlana Milton, MDAlana Milton, MDAlecia Jayne, AuDAlessandra Gasior, DOAlex Kemper, MDAlexandra Funk, PharmD, DABATAlexandra Sankovic, MDAlexis Klenke, RD, LDAlice Bass, CPNP-PCAlison PeggAllie DePoyAllison Rowland, AT, ATCAllison Strouse, MS, AT, ATCAmanda E. Graf, MDAmanda Smith, RN, BSN, CPNAmanda Sonk, LMTAmanda Whitaker, MDAmber Patterson, MDAmberle Prater, PhD, LPCCAmy Coleman, LISWAmy Dunn, MDAmy E. Valasek, MD, MScAmy Fanning, PT, DPTAmy Garee, CPNP-PCAmy Hahn, PhDAmy HessAmy Leber, PhDAmy LeRoy, CCLSAmy Moffett, CPNP-PCAmy Randall-McSorley, MMC, EdD CandidateAnastasia Fischer, MD, FACSMAndala HardyAndrea Brun, CPNP-PCAndrea M. Boerger, MEd, CCC-SLPAndrea Sattler, MDAndrew AxelsonAndrew Kroger, MD, MPHAndrew SchwadererAngela AbenaimAngela Billingslea, LISW-SAnn Pakalnis, MDAnna Lillis, MD, PhDAnnette Haban-BartzAnnie Drapeau, MDAnnie Temple, MS, CCC-SLP, CLCAnthony Audino, MDAnup D. Patel, MDAri Rabkin, PhDAriana Hoet, PhDArielle Sheftall, PhDArleen KarczewskiAshleigh Kussman, MDAshley EcksteinAshley Kroon Van DiestAshley M. Davidson, AT, ATC, MSAshley Minnick, MSAH, AT, ATCAshley Overall, FNPAshley Parikh, CPNP-PCAshley Parker MSW, LISW-SAshley Parker, LISW-SAshley Tuisku, CTRSAsuncion Mejias, MD, PhDAurelia Wood, MDBailey Young, DOBecky Corbitt, RNBelinda Mills, MDBenjamin Fields, PhD, MEdBenjamin Kopp, MDBernadette Burke, AT, ATC, MSBeth Martin, RNBeth Villanueva, OTD, OTR/LBethany Uhl, MDBethany Walker, PhDBhuvana Setty, MDBill Kulju, MS, ATBlake SkinnerBonnie Gourley, MSW, LSWBrad Childers, RRT, BSBrandi Cogdill, RN, BSN, CFRN, EMT-PBrandon MorganBreanne L. Bowers, PT, DPT, CHT, CFSTBrendan Boyle, MD, MPHBrian Boe, MDBrian K. Kaspar, PhDBrian Kellogg, MDBriana Crowe, PT, DPT, OCSBrigid Pargeon, MS, MT-BCBrittney Hardin, MOT, OTR/LBrooke Sims, LPCC, ATRCagri Toruner, MDCaitlin TullyCaleb MosleyCallista DammannCallista PoppCami Winkelspecht, PhDCanice Crerand, PhDCara Inglis, PsyDCarl H. Backes, MDCarlo Di Lorenzo, MDCarol Baumhardt, LMTCarrie Rhodes, CPST-I, MTSA, CHESCasey Cottrill, MD, MPHCasey TrimbleCassandra McNabb, RN-BSNCatherine Earlenbaugh, RNCatherine Sinclair, MDCatherine Trimble, NPCatrina Litzenburg, PhDCharae Keys, MSW, LISW-SCharles Elmaraghy, MDChelsie Doster, BSCheryl Boop, MS, OTR/LCheryl G. Baxter, CPNPCheryl Gariepy, MDChet Kaczor, PharmD, MBAChris Smith, RNChristina Ching, MDChristina DayChristine Johnson, MA, CCC-SLPChristine Mansfield, PT, DPT, OCS, ATCChristine PrusaChristopher Goettee, PT, DPT, OCSChristopher Iobst, MDChristopher Ouellette, MDCindy IskeClaire Kopko PT, DPT, OCS, NASM-PESCody Hostutler, PhDConnor McDanel, MSW, LSWCorey Rood, MDCorinne Syfers, CCLSCourtney Bishop. PA-CCourtney Hall, CPNP-PCCourtney Porter, RN, MSCrystal MilnerCurt Daniels, MDCynthia Holland-Hall, MD, MPHDana Lenobel, FNPDana Noffsinger, CPNP-ACDane Snyder, MDDaniel Coury, MDDaniel DaJusta, MDDaniel Herz, MDDanielle Peifer, PT, DPTDavid A Wessells, PT, MHADavid Axelson, MDDavid Stukus, MDDean Lee, MD, PhDDebbie Terry, NPDeborah Hill, LSWDeborah Zerkle, LMTDeena Chisolm, PhDDeipanjan Nandi, MD MScDenis King, MDDenise EllDennis Cunningham, MDDennis McTigue, DDSDiane LangDominique R. Williams, MD, MPH, FAAP, Dipl ABOMDonna Ruch, PhDDonna TeachDoug WolfDouglas McLaughlin, MDDrew Duerson, MDEd MinerEdward Oberle, MD, RhMSUSEdward Shepherd, MDEileen Chaves, PhDElise Berlan, MDElise DawkinsElizabeth A. Cannon, LPCCElizabeth Cipollone, LPCC-SElizabeth Zmuda, DOEllyn Hamm, MM, MT-BCEmily A. Stuart, MDEmily Decker, MDEmily GetschmanEmma Wysocki, PharmD, RDNEric Butter, PhDEric Leighton, AT, ATCEric Sribnick, MD, PhDErica Domrose, RD, LDEricca L Lovegrove, RDErika RobertsErin Gates, PT, DPTErin Johnson, M.Ed., C.S.C.S.Erin Shann, BSN, RNErin TebbenFarah W. Brink, MDGail Bagwell, DNP, APRN, CNSGail Besner, MDGail Swisher, ATGarey Noritz, MDGary A. Smith, MD, DrPHGeri Hewitt, MDGina Hounam, PhDGina McDowellGina MinotGrace Paul, MDGregory D. Pearson, MDGriffin Stout, MDGuliz Erdem, MDHailey Blosser, MA, CCC-SLPHanna MathessHeather Battles, MDHeather ClarkHeather Yardley, PhDHenry SpillerHenry Xiang, MD, MPH, PhDHerman Hundley, MS, AT, ATC, CSCSHiren Patel, MDHoma Amini, DDS, MPH, MSHoward Jacobs, MDHunter Wernick, DOIbrahim Khansa, MDIhuoma Eneli, MDIlana Moss, PhDIlene Crabtree, PTIrene Mikhail, MDIrina Buhimschi, MDIvor Hill, MDJackie Cronau, RN, CWOCNJacqueline Wynn, PhD, BCBA-DJacquelyn Doxie King, PhDJaime-Dawn Twanow, MDJames Murakami, MDJames Popp, MDJames Ruda, MDJameson Mattingly, MDJamie Macklin, MDJane AbelJanelle Huefner, MA, CCC-SLPJanice M. Moreland, CPNP-PC, DNPJanice Townsend, DDS, MSJared SylvesterJaysson EicholtzJean Hruschak, MA, CCC/SLPJeff Sydes, CSCSJeffery Auletta, MDJeffrey Bennett, MD, PhDJeffrey Hoffman, MDJeffrey Leonard, MDJen Campbell, PT, MSPTJena HeckJenn Gonya, PhDJennifer Borda, PT, DPTJennifer HofherrJennifer LockerJennifer PrinzJennifer Reese, PsyDJennifer Smith, MS, RD, CSP, LD, LMTJenny Worthington, PT, DPTJerry R. Mendell, MDJessalyn Mayer, MSOT, OTR/LJessica Bailey, PsyDJessica Bogacik, MS, MT-BCJessica Bowman, MDJessica BrockJessica Bullock, MA/CCC-SLPJessica Buschmann, RDJessica Scherr, PhDJim O’Shea OT, MOT, CHTJoan Fraser, MSW, LISW-SJohn Ackerman, PhDJohn Caballero, PT, DPT, CSCSJohn Kovalchin, MDJonathan D. Thackeray, MDJonathan Finlay, MB, ChB, FRCPJonathan M. Grischkan, MDJonathan Napolitano, MDJoshua Watson, MDJulee Eing, CRA, RT(R)Julia Colman, MOT, OTR/LJulie ApthorpeJulie Leonard, MD, MPHJulie Racine, PhDJulie Samora, MDJustin Indyk, MD, PhDKady LacyKaleigh Hague, MA, MT-BCKaleigh MatesickKamilah Twymon, LPCC-SKara Malone, MDKara Miller, OTR/LKaren Allen, MDKaren Days, MBAKaren Rachuba, RD, LD, CLCKari A. Meeks, OTKari Dubro, MS, RD, LD, CWWSKari Phang, MDKarla Vaz, MDKaryn L. Kassis, MD, MPHKasey Strothman, MDKatherine Deans, MDKatherine McCracken, MDKathleen (Katie) RoushKathryn Blocher, CPNP-PCKathryn J. Junge, RN, BSNKathryn Obrynba, MDKatie Brind’Amour, MSKatie Thomas, APRKatrina Hall, MA, CCLSKatrina Ruege, LPCC-SKatya Harfmann, MDKayla Zimpfer, PCCKelley SwopeKelli Dilver, PT, DPTKelly AbramsKelly BooneKelly HustonKelly J. Kelleher, MDKelly McNally, PhDKelly N. Day, CPNP-PCKelly Pack, LISW-SKelly Tanner,PhD, OTR/L, BCPKelly Wesolowski, PsyDKent Williams, MDKevin Bosse, PhDKevin Klingele, MDKim Bjorklund, MDKim Hammersmith, DDS, MPH, MSKimberly Bates, MDKimberly Sisto, PT, DPT, SCSKimberly Van Camp, PT, DPT, SCSKirk SabalkaKris Jatana, MD, FAAPKrista Winner, AuD, CCC-AKristen Armbrust, LISW-SKristen Cannon, MDKristen Martin, OTR/LKristi Roberts, MS MPHKristina Booth, MSN, CFNPKristina Reber, MDKyle DavisLance Governale, MDLara McKenzie, PhD, MALaura Brubaker, BSN, RNLaura DattnerLaurel Biever, LPCLauren Durinka, AuDLauren Garbacz, PhDLauren Justice, OTR/L, MOTLauren Madhoun, MS, CCC-SLPLauryn RozumLee Hlad, DPMLeena Nahata, MDLelia Emery, MT-BCLeslie Appiah, MDLinda Stoverock, DNP, RN NEA-BCLindsay Pietruszewski, PT, DPTLindsay SchwartzLindsey Vater, PsyDLisa GoldenLisa M. Humphrey, MDLogan Blankemeyer, MA, CCC-SLPLori Grisez PT, DPTLorraine Kelley-QuonLouis Bezold, MDLourdes Hill, LPCC-S Lubna Mazin, PharmDLuke Tipple, MS, CSCSLynda Wolfe, PhDLyndsey MillerLynn RosenthalLynne Ruess, MDMaggy Rule, MS, AT, ATCMahmoud Kallash, MDManmohan K Kamboj, MDMarc Levitt, MDMarc P. Michalsky, MDMarcel J. Casavant, MDMarci Johnson, LISW-SMarcie RehmarMarco Corridore, MDMargaret Bassi, OTR/LMaria HaghnazariMaria Vegh, MSN, RN, CPNMarissa Condon, BSN, RNMarissa LarouereMark E. Galantowicz, MDMark Smith, MS RT R (MR), ABMP PhysicistMarnie Wagner, MDMary Ann Abrams, MD, MPHMary Fristad, PhD, ABPPMary Kay SharrettMary Shull, MDMatthew Washam, MD, MPHMeagan Horn, MAMegan Brundrett, MDMegan Dominik, OTR/LMegan FrancisMegan Letson, MD, M.EdMeghan Cass, PT, DPTMeghan Fisher, BSN, RNMeika Eby, MDMelanie Fluellen, LPCCMelanie Luken, LISW-SMelissa and Mikael McLarenMelissa McMillen, CTRSMelissa Winterhalter, MDMeredith Merz Lind, MDMichael Flores, PhDMichael T. Brady, MDMike Patrick, MDMindy Deno, PT, DPTMitch Ellinger, CPNP-PCMolly Gardner, PhDMonica Ardura, DOMonica EllisMonique Goldschmidt, MDMotao Zhu, MD, MS, PhDMurugu Manickam, MDNancy AuerNancy Cunningham, PsyDNancy Wright, BS, RRT, RCP, AE-C Naomi Kertesz, MDNatalie Powell, LPCC-S, LICDC-CSNatalie Rose, BSN, RNNathalie Maitre, MD, PhDNationwide Children’s HospitalNationwide Children’s Hospital Behavioral Health ExpertsNeetu Bali, MD, MPHNehal Parikh, DO, MSNichole Mayer, OTR/L, MOTNicole Caldwell, MDNicole Dempster, PhDNicole Greenwood, MDNicole Parente, LSWNicole Powell, PsyD, BCBA-DNina WestNkeiruka Orajiaka, MBBSOctavio Ramilo, MDOliver Adunka, MD, FACSOlivia Stranges, CPNP-PCOlivia Thomas, MDOmar Khalid, MD, FAAP, FACCOnnalisa Nash, CPNP-PCOula KhouryPaige Duly, CTRSParker Huston, PhDPatrick C. Walz, MDPatrick Queen, BSN, RNPedro Weisleder, MDPeter Minneci, MDPeter White, PhDPitty JenningsPreeti Jaggi, MDRachael Morocco-Zanotti, DORachel D’Amico, MDRachel Schrader, CPNP-PCRachel Tyson, LSWRajan Thakkar, MDRaymond Troy, MDRebecca Fisher, PTRebecca Hicks, CCLSRebecca Lewis, AuD, CCC-ARebecca Romero ShakReggie Ash Jr.Reno Ravindran, MDRichard Kirschner, MDRichard Wood, MDRobert A. Kowatch, MD, Ph.D.Rochelle Krouse, CTRSRohan Henry, MD, MSRose Ayoob, MDRose Schroedl, PhDRosemary Martoma, MDRoss Maltz, MDRyan Ingley AT, ATCSamanta Boddapati, PhDSamantha MaloneSammy CygnorSandra C. Kim, MDSara Bentley, MT-BCSara Bode, MDSara Breidigan, MS, AT, ATCSara N. Smith, MSN, APRNSara O’Rourke, MOT, OTR/L, Clinical LeadSara Schroder, MDSarah A. Denny, MDSarah Cline, CRA, RT(R)Sarah Driesbach, CPN, APNSarah GreenbergSarah Hastie, BSN, RNC-NIC Sarah Keim, PhDSarah MyersSarah O’Brien, MDSarah SaxbeSarah Schmidt, LISW-SSarah ScottSarah TraceySarah VerLee, PhDSasigarn Bowden, MDSatya Gedela, MD, MRCP(UK)Scott Coven, DO, MPHScott Hickey, MDSean EingSean Rose, MDSeth Alpert, MDShana Moore, MA, CCC-AShannon Reinhart, LISW-SShari UncapherSharon Wrona, DNP, PNP, PMHSShawn Pitcher, BS, RD, USAWShawNaye Scott-MillerShea SmoskeSheila GilesSimon Lee, MDStacy Whiteside APRN, MS, CPNP-AC/PC, CPONStefanie Bester, MDStefanie Hirota, OTR/LStephanie Burkhardt, MPH, CCRCStephanie CannonStephanie Santoro, MDStephanie Vyrostek BSN, RNStephen Hersey, MDSteve Allen, MDSteven C. Matson, MDSteven Ciciora, MDSteven CuffSuellen Sharp, OTR/L, MOTSusan Colace, MDSusan Creary, MDSwaroop Pinto, MDTabatha BallardTabbetha GrecoTabi Evans, PsyDTabitha Jones-McKnight, DOTahagod Mohamed, MDTamara MappTammi Young-Saleme, PhDTerry Barber, MDTerry Bravender, MD, MPHTerry Laurila, MS, RPhTheresa Miller, BA, RRT, RCP, AE-C, CPFTThomas Pommering, DOThomas SavageTiasha Letostak, PhDTiffanie Ryan, BCBA Tim RobinsonTimothy Cripe, MD, PhDTracey L. Sisk, RN, BSN, MHATracie Rohal RD, LD, CDETracy Mehan, MATravis Gallagher, ATTrevor MillerTyanna Snider, PsyDTyler Congrove, ATVanessa Shanks, MD, FAAPVenkata Rama Jayanthi, MDVidu Garg, MDVidya Raman, MDW. Garrett Hunt, MDWalter Samora, MDWarren D. Lo, MDWendy Anderson, MDWendy Cleveland, MA, LPCC-SWhitney McCormick, CTRSWhitney Raglin Bignall, PhDWilliam Cotton, MDWilliam J. Barson, MDWilliam Ray, PhDWilliam W. Long, MD

My child was prescribed albuterol. What should I know about it? — Plateau Pediatrics

Albuterol is a medication that is used as a bronchodilator — it opens up tight airway passages by relaxing the muscle that surrounds the airways. Albuterol is used most commonly for asthma, but it is sometimes prescribed for other conditions too.

How long will my child need the albuterol?

In general, your child may need some albuterol as long as the wheezing trigger lasts. For illnesses that run their course (like bad colds), it may take about a week. On the other hand, if your child is frequently exposed to things that cause wheezing (like cigarette smoke or animal dander), it may seem like he or she always needs albuterol. (In that case, the best thing to do is to get rid of the allergic trigger!)

How often should I use albuterol?

In general, a dose of albuterol (either 2 puffs from an inhaler or one breathing treatment) may be given every four to six hours as needed. Give it for dry, hacking cough (especially nighttime cough), wheezing you can hear, or if your child is working harder to breathe. Unlike some other medicines, albuterol is safe to use occasionally on an as-needed basis. It can be started when there is a need for acute relief, tapered as the child improves, and stopped when he is better. However, if your child seems to need it very frequently for more than a day or two, doesn’t seem to be getting better with it, or seems to have frequent wheezing spells, he or she may need other medications and should be checked again in the office.

Remember, albuterol only helps one cause of cough: tight airways. It won’t help other kinds of coughs, like coughing from nasal drainage from a bad cold.

What side effects does albuterol have?

Most kids do well with it, but the most common side effects are rapid heartbeat, flushing, and jitteriness. In some kids, the jitteriness becomes hyperactivity! In most kids, these side effects wear off, or at least are much less bothersome, after about 10-15 minutes. If your child experiences side effects that are bad enough that you don’t want to give him or her albuterol, please let us know.

Should my child get albuterol through an inhaler or a nebulizer machine?

In general, inhalers (with spacers and masks) work better in most situations than nebulizer machines. They are also more convenient, since it only takes a minute to administer a few puffs from an inhaler (while it can take 10-15 minutes to give a breathing treatment.) Occasionally, there are some circumstances in which breathing treatments may work better, however. If you are not sure which method is best for your child, or need a demo on how to use one or both devices properly, ask us.

Does this mean my child has asthma?

Not every child who wheezes has asthma.

Many infants and toddlers wheeze with bad colds and other respiratory viruses but never wheeze again after they get to school-age. Other children who do have asthma start having wheezing spells as infants, and although it improves as they get older, they continue to have flare-ups from time to time as older kids. Because of this, we generally won’t diagnose asthma just based on one or two wheezing episodes in a baby or toddler.

Kids with true asthma tend to have other allergic symptoms (like eczema, food allergies, and allergic rhinitis) and family members with asthma. They tend to have persistent coughs, even when they don’t have cold or other illnesses. Learn more about asthma here.

What about liquid albuterol (by mouth)?

Albuterol also comes in a liquid form that can be taken by mouth, and a few doctors still use this for wheezing in babies. However, studies show it doesn’t give nearly as much relief as inhaled albuterol, so most pediatricians don’t use it anymore. Also, oral liquid albuterol tends to have more bothersome side effects than the inhaled method.

What about Xopenex?

Xopenex is the brand name of a kind of albuterol which is more concentrated than regular albuterol. There are a few studies which show its side effects may be slightly less bothersome than regular albuterol. However, it’s also about ten times as expensive as regular albuterol, which seems to work just as well for symptom relief in almost all kids.

Acute Bronchitis – American Family Physician

1. Meza RA,
Bridges-Webb C,
Sayer GP,
Miles DA,
Traynor V,
Neary S.
The management of acute bronchitis in general practice: results from the Australian Morbidity and Treatment Survey, 1990–1991. Aust Fam Physician.
1994;23:1550–3….

2. Kirkwood CR,
Clure HR,
Brodsky R,
Gould GH,
Knaak R,
Metcalf M,

et al.
The diagnostic content of family practice: 50 most common diagnoses recorded in the WAMI community practices. J Fam Pract.
1982;15(3):485–92.

3. Marsland DW,
Wood M,
Mayo F.
Content of family practice. Part 1. Rank order of diagnoses by frequency. J Fam Pract.
1976;3(1):37–68.

4. Dunlay J,
Reinhardt R.
Clinical features and treatment of acute bronchitis. J Fam Pract.
1984;18(5):719–22.

5. Gwaltney JM Jr. Acute bronchitis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:606–8.

6. Perlman PE,
Ginn DR.
Respiratory infections in ambulatory adults. Choosing the best treatment. Postgrad Med.
1990;87(1):175–84.

7. Williamson HA Jr.
A randomized, controlled trial of doxycycline in the treatment of acute bronchitis. J Fam Pract.
1984;19(4):481–6.

8. Evans AS,
Brobst M.
Bronchitis, pneumonitis, and pneumonia in University of Wisconsin students. N Engl J Med.
1961;265:401–9.

9. Evans AS,
Allen V,
Sueltmann S.
Mycoplasma pneumoniae infections in University of Wisconsin students. Am Rev Respir Dis.
1967;96:237–44.

10. Mogabgab WJ.
Mycoplasma pneumoniae and adenovirus respiratory illnesses in military and university personnel. Am Rev Respir Dis.
1968;97:345–58.

11. Hahn DL,
Dodge RW,
Golubjatnikov R.
Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA.
1991;266:225–30.

12. Falck G,
Heyman L,
Gnarpe J,
Gnarpe H.
Chlamydia pneumoniae (TWAR): a common agent in acute bronchitis. Scand J Infect Dis.
1994;26:179–87.

13. Williamson HA Jr.
Pulmonary function tests in acute bronchitis: evidence for reversible airway obstruction. J Fam Pract.
1987;25(3):251–6.

14. Williamson HA Jr,
Schultz P.
An association between acute bronchitis and asthma. J Fam Pract.
1987;24(1):35–8.

15. Stott NC,
West RR.
Randomised controlled trial of antibiotics in patients with cough and purulent sputum. Br Med J.
1976;2(6035):556–9.

16. Hueston WJ.
Antibiotics: neither cost effective nor “cough” effective. J Fam Pract.
1997;44(3):261–5.

17. Mello CJ,
Irwin RS,
Curley FJ.
Predictive values of the character, timing, and complications of chronic cough in diagnosing its cause. Arch Intern Med.
1996;156:997–1003.

18. Nelson EC,
Kirk JW,
Bise BW,
Chapman RJ,
Hale FA,
Stamps PL,

et al.
The cooperative information project: Part 2. Some initial clinical, quality assurance, and practice management studies. J Fam Pract.
1981;13(6):867–76.

19. Mainous AG 3d,
Zoorob RJ,
Hueston WJ.
Current management of acute bronchitis in ambulatory care: the use of antibiotics and bronchodilators. Arch Fam Med.
1996;5:79–83.

20. Orr PH,
Scherer K,
Macdonald A,
Moffatt ME.
Randomized placebo-controlled trials of antibiotics for acute bronchitis: a critical review of the literature. J Fam Pract.
1993;36(5):507–12.

21. Brickfield FX,
Carter WH,
Johnson RE.
Erythromycin in the treatment of acute bronchitis in a community practice. J Fam Pract.
1986;23(2):119–22.

22. Dunlay J,
Reinhardt R,
Roi LD.
A placebo-controlled, double-blind trial of erythromycin in adults with acute bronchitis. J Fam Pract.
1987;25(2):137–41.

23. Franks P,
Gleiner JA.
The treatment of acute bronchitis with trimethoprim and sulfamethoxazole. J Fam Pract.
1984;19(2):185–90.

24. King DE,
Williams WC,
Bishop L,
Shechter A.
Effectiveness of erythromycin in the treatment of acute bronchitis. J Fam Pract.
1996;42(6):601–5.

25. Vinson DC,
Lutz LJ.
The effect of parental expectations on treatment of children with a cough: a report from ASPN. J Fam Pract.
1993;37(1):23–7.

26. Hamm RM,
Hicks RJ,
Bemben DA.
Antibiotics and respiratory infections: are patients more satisfied when expectations are met? J Fam Pract.
1996;43(1):56–62.

27. Anthonisen NR,
Manfreda J,
Warren CP,
Hershfield ES,
Harding GK,
Nelson NA.
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med.
1987;106:196–204.

28. Saint S,
Bent S,
Vittinghoff E,
Grady D.
Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA.
1995;273:957–60.

29. Nicotra MB,
Kronenberg RS.
Con: antibiotic use in exacerbations of chronic bronchitis. Semin Respir Infect.
1993;8:254–8.

30. Staley H,
McDade HB,
Paes D.
Is an objective assessment of antibiotic therapy in exacerbations of chronic bronchitis possible? J Antimicrob Chemother.
1993;31:193–7.

31. Pozzi E.
Clinical efficacy of dirithromycin versus miocamycin in the treatment of acute bronchitis or acute exacerbations of chronic bronchitis. J Antimicrob Chemother.
1993;31(Suppl C):153–8.

32. Melbye H,
Aasebo U,
Straume B.
Symptomatic effect of inhaled fenoterol in acute bronchitis: a placebo-controlled double-blind study. Fam Pract.
1991;8(3):216–22.

33. Hueston WJ.
A comparison of albuterol and erythromycin for the treatment of acute bronchitis. J Fam Pract.
1991;33(5):476–80.

34. Hueston WJ.
Albuterol delivered by metered-dose inhaler to treat acute bronchitis. J Fam Pract.
1994;39(5):437–40.

35. Littenberg B,
Wheeler M,
Smith DS.
A randomized controlled trial of oral albuterol in acute cough. J Fam Pract.
1996;42:49–53.

36. Hahn DL,
Anttila T,
Saikku P.
Association of Chlamydia pneumoniae IgA antibodies with recently symptomatic asthma. Epidemiol Infect.
1996;117:513–7.

37. Bavastrelli M,
Midulla M,
Rossi D,
Salzano M.
Chlamydia trachomatis infection in children with wheezing simulating asthma [Letter]. Lancet.
1992;339:1174.

38. Emre U,
Roblin PM,
Gelling M,
Dumornay W,
Rao M,
Hammerschlag MR,

et al.
The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med.
1994;148:727–32.

39. Hahn DL.
Treatment of Chlamydia pneumoniae infection in adult asthma: a before-after trial. J Fam Pract.
1995;41(4):345–51.

All about Albuterol: What Parents Should Know about Inhalers, Spacers, and Nebulizers

If your child was prescribed albuterol for asthma or another respiratory condition, here’s what you need to know about the medicine.

The bronchial tubes, the tubes leading to the lungs, are supposed to be open and relaxed, but many children have illnesses that cause the muscles around the bronchial tubes to squeeze tight and restrict airflow. Because this makes it more difficult for kids to get air in and out, children experiencing this problem will wheeze or cough.  

Albuterol is a prescription drug that is used as a “bronchodilator,” meaning that it opens up the bronchial tubes to allow air to flow in and out easily. Albuterol alleviates these symptoms by relaxing the muscles around the airways. Your child’s pediatrician may prescribe albuterol for a variety of breathing problems, including asthma and allergy-related wheezing. If you’re a parent of a child with asthma or another respiratory issue, here’s what you can expect when your child is using albuterol:

Dosage and Side Effects of Albuterol 

Typically, a pediatrician will recommend that you administer albuterol for every four to six hours for as long as it’s needed. If your child has an acute illness, this may take about a week. If your child has allergies or a chronic illness like asthma, your doctor may recommend that you administer albuterol any time he or she is exposed to a wheezing trigger. Unlike some other medications, it is generally safe to use albuterol as needed; there is no weaning period.  

Most children experience few or only very mild side effects when using albuterol. The most common side effects include rapid heartbeat, flushing, or jitteriness, which can present as hyperactivity in some children. For most children, these side effects will wear off in under 15 minutes. If they persist for significantly longer, it’s a good idea to get in touch with your pediatrician, especially if the symptoms make you reluctant to administer the medicine.

Albuterol can be inhaled or consumed in liquid form. In general, liquid albuterol is used for infants, but it doesn’t provide as much relief as inhaled albuterol and may have more intense side effects. Most doctors will recommend inhaled albuterol for a wheezing child, which can be administered via inhaler, inhaler and spacer, or nebulizer.

Albuterol Administration Methods

• Inhaler: Inhalers are the most common means of administering albuterol. Typically, an inhaler will be shaped like a boot; one end will be a mouthpiece and the other end contains a canister of medicine. Patients deliver a dose of medication by pushing down on the canister or by breathing in, depending on the type of inhaler. 

When used correctly, albuterol can provide enormous relief for children who are struggling with asthma or other breathing issues. If your child is wheezing, coughing, or showing signs of chronic respiratory distress, contact Kids’ Health to schedule an appointment. 

…
90,000 Use of bronchodilators for bronchiolitis in infants with the first episode of wheezing

What is bronchiolitis?

Bronchiolitis is an acute, highly contagious (contagious) viral lung disease that affects children aged 0 to 12 months. It occurs every year during the winter months. and causes inflammation of the small airways in the lungs (small bronchi) and filling them with mucus. The airways are narrowed and this leads to a blockage of the free passage of air.The infant develops a severe cough, runny nose, and usually a fever. He / she may begin to choke, wheeze and suffer from a lack of oxygen (experience hypoxia).

Why consider bronchodilators?

Bronchodilators are drugs that are often used as aerosols to widen the airways by relaxing the muscles of the bronchi. They are effective in treating asthma in older children and adults. However, unlike asthmatics, babies with bronchiolitis usually have wheezing for the first time.They wheeze for another reason, because their airways are filled with mucus. Thus, children with bronchiolitis are less likely to respond to bronchodilators.

Study characteristics

We reviewed the evidence for the effect of bronchodilators on bronchiolitis in infants. We found 30 clinical trials in which a total of 1922 children from several countries took part. Evidence is valid until January 2014. We analyzed outpatient and inpatient studies separately.All bronchodilators except epinephrine were included in the review because it was reviewed in another Cochrane review. Albuterol (otherwise known as salbutamol) is commonly used in research, so we also looked at this bronchodilator as a subgroup.

Key results

We found no effect of bronchodilators on the saturation of the airways with oxygen (oxygen saturation). In hospitalized infants with bronchiolitis, there was no significant benefit from bronchodilator treatment.This review also found that bronchodilators do not reduce the need for hospitalization, do not shorten the length of hospital stay and the duration of illness when treated at home. Looking at the subset of studies on albuterol (salbutamol), we found no effect of this bronchodilator on oxygen saturation or clinical performance. Side effects of bronchodilators include increased heart rate, decreased oxygen levels, and tremors. Given these side effects, the small amount of evidence that bronchodilators are effective, and the costs associated with these treatments, we concluded that bronchodilators are not helpful in treating bronchiolitis.

Quality of evidence

This review is limited to a small number of studies using the same criteria and methods. For example, only 22 studies included only infants experiencing wheezing (whistling) for the first time. Previous studies have included children who have had wheezing in the past and may have had asthma, and thus these earlier studies favor the use of bronchodilators. Newer studies that excluded infants with prior wheezing episodes and had a better study design did not show the benefit of bronchodilators.This review is also limited to the small number of participants included in each study. Finally, in some studies, the clinical indicators used to assess the effect of bronchodilators may differ from one investigator to the next, making this estimate unreliable. To determine the effectiveness of these drugs, studies are needed that include more infants, better scores, and a more rigorous study design.

Acute uncomplicated bronchitis.The ABC of antibiotic therapy. Vidal reference book of medicines

90,000 Asthma drug could be a breakthrough in the treatment of COVID-19 | Coronavirus of a new type SARS-CoV-2 and the COVID-19 pandemic | DW

A steroid called budesonide, which is used in inhalers for patients with bronchial asthma, is also effective in relieving symptoms of COVID-19 at an early stage.This is stated in a study by the University of Oxford, published in mid-April 2021 in the authoritative medical journal The Lancet.

According to scientists, patients with COVID-19 who start taking budesonide at the first symptoms of the disease are less likely to need hospitalization and recover faster. In addition, symptoms of COVID-19, including high fever, go away faster than patients who are treated with traditional methods.

A randomized controlled trial by Oxford scientists enrolled 146 adult patients with mild symptoms of COVID-19, which began to appear in them no earlier than a week before the start of the study.Half of the participants took budesonide twice a day until they had no symptoms. The other half received conventional treatment, taking into account their age and existing medical conditions.

As a result, only one patient in the first group required emergency medical care. At the same time, among 73 people who were treated for COVID-19 using traditional methods, there were 10 such patients.

Steroids reduce the risk of inflammation in COVID-19

As noted in an interview with DW, Dr. Institute of Heart and Lung Disease, Imperial College London, the fact that corticosteroids (steroid hormones produced by the adrenal cortex) are effective in treating COVID-19 can be explained by biological reasons.Dr. Bloom did not participate in the above study at Oxford University.

Early treatment of COVID-19 will help prevent hospital overload

According to the expert, corticosteroids such as dexamethasone are already being effectively used to treat patients with complications from COVID-19. Scientists believe these drugs reduce the risk of inflammation that occurs when COVID-19 is severe. It is likely that budesonide has a similar effect, albeit more locally, Bloom points out.

Another positive effect of steroids used in inhalers, according to scientists, is the reduced risk of SARS-CoV-2 virus entering the lungs of patients with asthma or chronic obstructive pulmonary disease. At the same time, laboratory studies have confirmed that such drugs prevent the multiplication of the virus in the body.

Hope to unload hospitals

Mona Bafadhel, co-author of the Oxford study on budesonide and assistant professor of pulmonary medicine at the University of Oxford, stresses that the steroid is inexpensive, widely available and relatively safe.According to the expert, using it in the early stages of the COVID-19 disease will help relieve the hospitals that receive patients with complications after being infected with the coronavirus.

WHO Deputy Director Sumiya Swaminatan called the study on budesonide encouraging

In Germany, the results of the Oxford study were also highly appreciated by individual experts. For example, a deputy from the Social Democratic Party of Germany (SPD), ex-epidemiologist Karl Lauterbach (Karl Lauterbach) said on his Twitter page that it could “radically change the situation”, including because it determines the treatment of COVID-19 in the early stages.

For her part, World Health Organization (WHO) Deputy Director General for Programs Sumiya Swaminathan called the study results “encouraging” and encouraged further exploration of outpatient treatment for COVID-19 patients.

It is noted that the University of Oxford, due to the lockdown that began in the UK and some other factors, had to stop the study at an early stage. However, independent experts who evaluated the results of this scientific work concluded that the conclusions would not have been influenced by the involvement of more participants.

What are corticosteroids

The human body produces corticosteroids on its own. Synthetically synthesized variants of these hormones are used in medicine to treat many inflammatory diseases. Typically, corticosteroid-based drugs are prescribed by inhalation for patients with asthma and other respiratory conditions. They are listed by WHO on the list of critical drugs.

See also:

• How Europe is fighting the second wave of coronavirus

  Europe is swept by the second wave of coronavirus

  With the arrival of autumn, the number of new cases of coronavirus infection skyrocketed: by November, in many European countries, daily growth was calculated in dozens thousands of cases.Amid the surge in COVID-19, more and more countries are re-imposing multiple restrictions in an effort to slow the spread of the coronavirus and prevent the collapse of the healthcare system.

• How Europe is fighting the second wave of coronavirus

  Germany: soft lockdown

  By the beginning of November, a new anti-record for the number of infections was set in Germany – the daily increase in SARS-CoV-2 infected exceeded 20 thousand. In an attempt to reduce it, the authorities introduced a soft lockdown on November 2.Chancellor Angela Merkel called on the country’s residents to understand the need for the introduced anti-epidemiological measures. By mid-November, daily rates began to decline.

• How Europe is fighting the second wave of coronavirus

  Germany: clubs and gyms are closed, restaurants are open only for takeaway

  A soft or partial lockdown in Germany mainly affected the sphere of leisure and entertainment: clubs, discos, gyms and theaters are closed; restaurants, cafes and bars can only sell takeaway.Schools and kindergartens continue to operate. The restrictions are expected to be in effect until the end of November.

• How Europe is fighting the second wave of coronavirus

  Masks: a constant attribute of autumn wardrobe

  Wearing protective masks remains one of the main requirements of social distancing in Germany. In many German cities, they now need to be worn not only on public transport, but also on busy streets. Violation of this rule is subject to fines ranging from 50 to 250 euros – depending on the federal state.

• How Europe is fighting the second wave of coronavirus

  Russia: anti-records in the number of infections and deaths

  The daily increase in coronavirus infections in the Russian Federation exceeded 22 thousand by November. On November 17, an anti-death record was recorded in the country – 442 people died from the consequences of COVID-19 per day. The regions are struggling to cope with the second wave: the media write that in some hospitals beds and cots are placed in the corridors, patients do not have enough oxygen, and they have to wait for an ambulance for days.

• How Europe is fighting the second wave of coronavirus

  Moscow has one of the most severe restrictions in the Russian Federation

  Despite the anti-records of the number of SARS-CoV-2 infected, the lockdown in the Russian Federation is not going to be announced yet, introducing point restrictions at the regional level … Some of the most severe are in Moscow. Since November 13, bars and restaurants in the capital cannot work at night, universities have been transferred to a remote location, and visits to “cultural, exhibition, educational events” are prohibited.The restrictions will last until January 15, 2021.

• How Europe is fighting the second wave of coronavirus

  Belarus: mass demonstrations in the context of the pandemic

  Against the background of the growth of SARS-CoV-2 infections in Belarus, its residents continue to go to protest actions of many thousands. Lukashenko has already accused the protesters of complicating the fight against COVID-19. The authorities are silent about the mass detentions and arrests of demonstrators and the unsanitary conditions in the pre-trial detention center.By November 14, the daily increase in diseases exceeded 1200 cases. Many consider the statistics to be understated.

• How Europe is fighting the second wave of coronavirus

  Ukraine: the film industry and restaurant business are afraid not to survive the weekend lockdown

  The level of daily coronavirus infections in Ukraine reached its maximum since the beginning of the pandemic, exceeding 12 thousand by mid-November. The country has introduced a weekend lockdown: only grocery stores, pharmacies, transport and gas stations are open on Saturdays and Sundays.Restaurants, bars and cafes can sell takeaway. Restaurateurs, film industry and trade representatives fear for their business.

• How Europe is fighting the second wave of coronavirus

  Austria: hard lockdown until December 6

  In the fight against coronavirus, the Austrian authorities have introduced a hard lockdown. From November 17 to December 6, leaving the house is allowed only for certain reasons – for example, to visit grocery stores and pharmacies, travel to work, to see a doctor.Walking and jogging are also allowed. All shops except supermarkets are closed, pharmacies, banks and gas stations will continue to operate.

• How Europe is fighting the second wave of coronavirus

  France: COVID-19 patients are sent for treatment to Germany

  France is the fourth in the world in terms of the spread of coronavirus. Since the beginning of the pandemic, 1.9 million infections have been detected here. The country’s healthcare system is overloaded, some patients are transported to Germany for treatment.A lockdown has been in effect in the country since the end of October. Residents are given one hour a day to go to the store, see a doctor, or walk within a radius of no more than one kilometer from their home.

• How Europe is fighting the second wave of coronavirus

  Sweden: coronavirus became the third most common cause of death

  In the first half of 2020, the consequences of coronavirus infection became the third most common cause of death in Sweden. About 10 percent of the total number of deaths in the country died from the consequences of COVID-19, according to the report of the Ministry of Health.

• How Europe is fighting the second wave of coronavirus

  Italy: hugs with parents through a plastic curtain

  Italy is among the ten countries most affected by the coronavirus. The number of infections since the beginning of the pandemic has exceeded one million. A curfew has been in effect in the country since November. The territory of Italy is divided into three risk zones, in the regions of the “red zone” – a partial lockdown. Many nursing homes are closed to the public. In one of them, a room was equipped with plastic curtains for people to hug.

• How Europe is fighting the second wave of coronavirus

  Denmark: minks became victims of the coronavirus

  The Danish authorities ordered the destruction of all minks on the country’s farms. The reason was the mutated SARS-CoV-2 coronavirus found in minks, which spreads to humans and reduces the ability to form antibodies. Denmark is the world’s largest producer of mink fur. There are 1,139 mink farms in the country, which in total are home to about 15-17 million minks.

• How Europe is fighting the second wave of coronavirus

  Light at the end of the tunnel: vaccines against coronavirus may appear as early as 2021

  The German pharmaceutical company BioNTech and the American corporation Pfizer announced on November 9 that the vaccine they have developed has shown effectiveness in 90%. A week later, the American firm Moderna announced that its vaccine was 95% effective. Both companies intend to apply for accelerated drug registration in the United States.It is hoped that the vaccine will be available as early as 2021.

  Author: Marina Baranovskaya

.